Analyst Etzer Darout works at BMO and is focused on the Healthcare sector with 69 price targets and ratings documented since 2018 spanning on 15 stocks. Previously, Etzer Darout worked at GUGGENHEIM. Analyst's average stock valuation to be materialised ratio is 38.89% with an average time for price targets to be met of 80.13 days.
Most recent stock forecast was given on IMGN, ImmunoGen, Inc at 16-Nov-2022.
Etzer Darout best performing recommendations are on NUVL.
The best stock recommendation documented was for MGNX (MACROGENICS, INC) at 6/1/2020. The price target of $30 was fulfilled within 36 days with a profit of $8.9 (42.18%) receiving and performance score of 11.72.
Average potential price target upside